What drug interactions does Jakafi (ruxolitinib) have?
Jakafi (ruxolitinib) is metabolized mainly by the liver enzyme CYP3A4 and can also interact with drug transporters. That means interactions can happen when other medicines either increase or decrease CYP3A4 activity, or when drugs affect how ruxolitinib is transported in the body.
Because of this, two interaction patterns are most important:
- Strong CYP3A4 inhibitors (they can raise ruxolitinib levels and increase side-effect risk)
- CYP3A4 inducers (they can lower ruxolitinib levels and reduce effect)
Which medicines most increase Jakafi levels (CYP3A4 inhibitors)?
Medicines that inhibit CYP3A4 can increase ruxolitinib exposure, which can raise the risk of adverse effects. Common categories that are often involved include certain antifungals and some antivirals, plus some macrolide antibiotics.
If you take a strong CYP3A4 inhibitor, clinicians typically reduce the Jakafi dose and monitor closely for toxicity.
Which medicines reduce Jakafi levels (CYP3A4 inducers)?
Medicines that induce CYP3A4 can lower ruxolitinib concentrations, which may reduce its effectiveness. Inducer categories that are commonly involved include some seizure medications (antiepileptics) and other drugs known to boost CYP3A4 activity.
In practice, prescribers may avoid these combinations when possible, or adjust therapy based on response and tolerability.
What about other interaction mechanisms (transporters and overlapping toxicity)?
Jakafi interactions can also be influenced by drug transporters in addition to CYP3A4. Separate from pharmacokinetic interactions, there is also the issue of overlapping side effects.
For example, combining Jakafi with other therapies that suppress blood cells can increase risk of anemia, neutropenia, or thrombocytopenia. If you use multiple drugs that affect the same lab values, your clinician will usually check blood counts more often.
Can antibiotics, antifungals, or antivirals interact with Jakafi?
Yes. Several antibiotics, antifungals, and antivirals can act as CYP3A4 inhibitors or inducers, which is why your medication list matters. The interaction can be clinically significant enough that the Jakafi dose or monitoring plan changes.
A practical approach is to tell your clinician or pharmacist every prescription and over-the-counter product you use, including “as needed” antifungals, antibiotics, and antiviral regimens.
What should patients do before starting a new medication?
Before adding any new drug to a current Jakafi regimen, it’s best to:
- Confirm whether the new medicine is a strong or moderate CYP3A4 inhibitor/inducer
- Ask whether Jakafi dose adjustment is needed
- Arrange the right follow-up monitoring (often including blood counts and clinical response)
What if I’m already on interacting drugs?
If you are already taking a medicine known to inhibit or induce CYP3A4, do not stop Jakafi or the other drug on your own. Contact the prescriber promptly so they can determine whether:
- Jakafi dose needs adjustment,
- additional monitoring is required,
- or an alternative medication is safer.
Side effects that can signal an interaction
When Jakafi levels rise (often from CYP3A4 inhibition), side effects related to ruxolitinib exposure become more likely. Patients should report worsening:
- fatigue or shortness of breath (possible anemia),
- fever or infections (possible low white cells),
- unusual bruising/bleeding (possible low platelets),
- severe or persistent gastrointestinal symptoms.
Tell me your exact medicines to identify likely interactions
If you share the other drugs you take (names and doses, including OTCs and supplements like St. John’s wort), I can help flag which ones are most likely to interact and what clinicians typically do about them.